University of Manitoba
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1877-02-28
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.umanitoba.ca
Clinical Trials
538
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (459 trials with phase data)• Click on a phase to view related trials
Evaluating and Implementing The CONNECT Program - a Group-Based Telehealth Intervention to Reduce Social Isolation, Loneliness, and Mental Health Symptoms in Adults Ages 55+, Compared to Routine Community-Based Programming
- Conditions
- LonelinessSocial IsolationDepression DisordersAnxiety
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 128
- Registration Number
- NCT07107906
Perioperative Virtual Reality Intervention for Pain and Anxiety During Vasectomies
- Conditions
- VasectomyPainAnxietyVirtual Reality
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 90
- Registration Number
- NCT07055178
- Locations
- 🇨🇦
Manitoba Men's Health Clinic, Winnipeg, Manitoba, Canada
Advancing Family Wellbeing Through a Massive Open Online Intervention: The LightBEAM Program
- Conditions
- AngerParentingDepression, AnxietyStress PsychologicalParent Child RelationshipChild Development
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 300
- Registration Number
- NCT07026838
- Locations
- 🇨🇦
University of Manitoba, Winnipeg, Manitoba, Canada
CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children
- Conditions
- Drug Resistant Epilepsy
- Interventions
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 90
- Registration Number
- NCT07023744
Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period
- Conditions
- Benign Prostate Hypertrophy(BPH)
- Interventions
- Drug: Beta-3 agonists (Mirabegron/Myrbetriq)Other: Placebo group post rezum
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 50
- Registration Number
- NCT07017439
- Locations
- 🇨🇦
Men's Health Clinic Manitoba, Winnipeg, Manitoba, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 108
- Next
News
Theralase's Ruvidar® Shows Complete Healing of HSV-1 Lesions in Preclinical Study
Theralase's topical Ruvidar® treatment demonstrated complete healing of HSV-1 cutaneous lesions in mice after four days of application, marking a significant breakthrough in herpes treatment.
Risk Stratification and Population Health Key to Revolutionizing CKD Care Management
Advanced risk stratification models are enabling precise identification of high-risk CKD patients and connecting them with appropriate therapies, bridging the gap between diagnostics and treatment.